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Abstract: 
A simple, highly sensitive, precise and accurate high-performance liquid chromatographic (LCMSMS) method with 
mass detection was developed and validated for the rapid quantiication of metaxalone (CAS Registry No, 1665-48-
1) in rat plasma samples. The chromatographic separation was achieved with a reverse phase column Agilent XDB 
C18 (4.6×100 mm, 5µ) and the mobile phase consisted of methanol and 5 mm ammonium acetate buffer (80:20 v/v) 
as eluent, at a low rate of 0.6 mL/min. Phenytoin (CAS Registry no, 57-41-0) was used as an internal standard. The 
efluence was ionized by positive electrospray ionization and measured by mass spectrometry. The retention time of 
metaxalone and phenytoin were found to be 1.60 and 1.83 min respectively. The calibration curve was linear (r2 > 
or = 0.99) ranging from 0.98 to 998 ng/ml and the lower limit of quantiication was 0.98 ng/mL. Interday and 
Intraday precision were lower than 5% (CV) and accuracy ranged from 90 to 110% in terms of percent accuracy. 
Mean extraction recovery was found to be above 82%. The method was successfully demonstrated for evaluation of 
pharmacokinetic proile of metaxalone in male Sprague dawley rats and validated for excellent selectivity, accuracy, 
precision, recovery and stability. 
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INTRODUCTION: 
Metaxalone has the molecular formula C12H15NO3 
and chemical name 5-[(3,5-
dimethylphenoxy)methyl]-2-oxazolidinone) with a 
molecular mass of 221.26 g/mol and absorption 
maxima around 280 nm. Metaxalone belong to the 
BCS class II of centrally acting skeletal muscle 
relaxant drug with antispasmodic efect [1]. 
Metaxalone belongs to non benzodiazepine 
antispasmodics with a structure similar to 
mephenaxalone nucleus [2]. Metaxalone (skelaxin) 
got FDA approval in 1962 by King Pharmaceuticals 
mainly for the treatment of acute, painful and 
musculoskeletal conditions like fractures, 
dislocations, and trauma to tendons and ligaments 
and other measures for the relief of discomforts [3]. 
he mode of action of the metaxalone is clearly 
unknown but hypothesized as CNS depressant drug 
which causes skeletal muscle relaxation and sedation 
[4]. It acts through inhibiting interneuronal activity 
and blocking polysynaptic relex pathways at spinal 
cord and at descending reticular formation in brain 
but leaving monosynaptic pathways intact like other 
similar class of skeletal muscle relaxants [5,6]. 
Metaxalone directly does not cause any relaxant efect 
on tense skeletal muscles or on the contractile 
mechanism of striated muscle, the motor end plate or 
the nerve iber in humans. 
Metaxalone has the advantage of reduced sedation, 
abusing potential and limited accumulation because 
of its short biological half life [7]. Orally 
administered metaxalone shows improved exposure 
(AUC and Cmax) ater standardized high fat meal. 
Metaxalone has extensive tissue distribution and gets 
metabolized in liver and excreted through urine [8]. 
he drug is not recommended for patients with 
signiicant renal, hepatic disease and drug induced 
anaemias [9]. 
Literature survey has revealed that there only few 
methods were reported for the determination of 
metaxalone in plasma by liquid chromatography. 
Methods reported in the literature for the estimation 
of metaxalone in bulk and biological luids include sot 
ionization interfaces like electrospray ionization 
(ESI) for determining metaxalone (LC-MS/MS) [10], 
ultraviolet spectroscopy with LC Chromatography 
method (HPLC-UV) [11], gas chromatography with 
lame ionization detection [12,13], gas 
chromatography with mass detection [13,14]. he 
quantiication of drugs, metabolites and poisonous 
chemicals from biological luids using mass 
spectrometry has gained importance in forensic 
toxicology, clinical and pharmaceutical sector for 
wide range of application [15]. 
From the literature survey, reported methods are 
mainly designed for human biological samples  
 
typically above 0.2 mL of human plasma reveals the 
usage of high quantity of sample in terms of volume, 
high solvent consumption and tedious sample 
processing includes control of the factors like pH, 
extraction solvent, evaporating temperature which is 
highly time consuming and laborious analysis. 
Consequently, in rodents very little plasma volume 
would be available from each animal for processing. 
Under the scope of this view, aim of our research 
work is to develop a highly speciic, reliable and 
sensitive method for metaxalone determination in rat 
plasma that proves to be of immense importance for 
conducting preclinical studies eiciently in terms of 
less sample volume, short run time, less tedious 
processing and sensitive analysis. Hence, a highly 
sensitive isocratic LC-MS/MS method was developed 
and validated according to the international 
guidelines for quantifying metaxalone in rat plasma 
at a concentration range (0.98 ng/mL). Furthermore, 
a pharmacokinetics study of metaxalone in rat model 
was conducted, in order to validate the method in 
study samples. 
Literature profile of selected drugs  
Drug name: Fulvestrant 
Chemical Formula: C32H47F5O3S 
Chemical Structure: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IUPAC Name: 7-alpha-[9-(4,4,5,5,5-penta 
fluoropentyl sulphinyl) nonyl]estra-1,3,5-(10)-
triene 3,17beta-diol. 
Average Molecular Weight: 606.771 g/mol 
Water Solubility: 9.53*10-6 mg/ml at 250c 
LogP/Hydrophobicity: 9.09 
pKa Value: 10.32 
Drug Category: Antineoplastic Agents, 
Antiestrogen 
Pharmacology: 
Indication: For the treatment of hormone receptor 
positive metastatic breast cancer in postmenopausal 
women with disease progression following anti-
estrogen therapy.  
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Pharmacodynamics:  
Fulvestrant for intramuscular administration is an 
estrogen receptor antagonist without known agonist 
effects. 
Protein Binding: 99% (mainly VLDL, LDL, and 
HDL) 
Mechanism of action: 
Fulvestrant competitively and reversibly binds to 
estrogen receptors present in cancer cells and 
achieves its anti-estrogen effects through two 
separate mechanisms. First, Fulvestrant binds to the 
receptors and down regulates them so that estrogen is 
no longer able to bind to these receptors. Second, 
fulvestrant degrades the estrogen receptors to which 
it is bound. 
Volume of distribution: 3 to 5 L/kg 
 Metabolism: Metabolism of fulvestrant appears to 
involve combinations of a number of possible 
biotransformation pathways analogous to those of 
endogenous steroids, including oxidation, aromatic 
hydroxylation, conjugation with glucuronic acid 
and/or sulphate at the 2, 3 and 17 positions of the 
steroid nucleus, and oxidation of the side chain 
sulphoxide. Identified metabolites are either less 
active or exhibit similar activity to fulvestrant in 
antiestrogen models. Studies using human liver 
preparations and recombinant human enzymes 
indicate that cytochrome P-450 3A4 (CYP 3A4) is 
the only P-450 isoenzyme involved in the oxidation 
of fulvestrant; however, the relative contribution of 
P-450 and non-P-450 routes in vivo is unknown. 
Half life: 40 days 
Dosage Forms: Solution (injectable) (125&250 
mg/2.5ml syringe) 
Route of administration: Intramuscular 
Route of elimination: Fulvestrant was rapidly 
cleared by the hepatobiliary route with 
excretion primarily via the feces 
(approximately 90%). Renal elimination was 
negligible (less than 1%). 
Marketed products: Faslodex 
Drug name: Letrozole 
Chemical Formula: C17H11N5 
Chemical Structure: 
 
 
 
 
 
 
 
 
 
 
 
 
IUPAC Name: 4-[(4-cyanophenyl)(1H-1,2,4-
triazol-1-yl)methyl]benzonitrile 
Average Molecular Weight: 285.3027 g/mol 
Water Solubility: 102 mg/L at 250c 
LogP/Hydrophobicity: 2.22 
pKa Value: 2.17 
 
MATERIALS AND METHODS 
Chemicals and reagents 
Metaxalone (CAS Registry No, 1665-48-1) (Figure 
1) of the highest quality has been purchased from 
sigma Aldrich (Mumbai, India) and Phenytoin 
(Internal Standard) (CAS Registry no, 57-41-0) 
(Figure 1) was kindly donated by Torrent 
Pharmaceuticals limited (Ahmedabad, India). HPLC 
grade Methanol 99.8% was obtained from Merck 
chemicals (Bangalore, India). Water was puriied 
through a Milli-Q UV plus system supplied by 
Millipore Pvt Ltd (Bangalore, India). Ammonium 
acetate, Acetic acid and Trichloroacetic acid were of 
analytical reagent grade supplied by Merck 
Chemicals (Bangalore, India) and SD ine chemicals 
(Mumbai, India) respectively. 
 
Instrumentation 
LC-MS/MS analysis was performed on Applied 
Biosystems/MDS SCIEX API 4000 LC-MS/MS 
triple quadrupole mass spectrometry with ESI source 
and is enhanced by the high degree of automation and 
data processing capabilities of Analyst sotware 
supplied by Labindia Instrument Pvt. Ltd. (Gurgaon, 
India). he LC part consists of Shimadzu auto sampler 
LC-10 series chromatographic system (Shimadzu 
Corporation, Kyoto, Japan) equipped with dual pump 
(LC10AT-VP). he column oven employed (CTO-
10AS VP) and vacuum suction pump was Varian HS 
602 Vacuum Pump supplied by Agilent Technologies 
India Pvt. Ltd. (Haryana, India) 
 
Chromatographic condition 
Chromatographic separations were achieved by using 
Agilent XDB C18 column (100×4.6 mm, 5 µm).he 
mobile phase consisted of methanol and 5 mm 
ammonium acetate bufer in the ratio of 80:20 v/v. he 
rinsing solution used was made of methanol and 
water (80:20) with 0.05% acetic acid. All separations 
were performed isocratically at a low rate of 0.6 
mL/min and the injection volume was 5 µl. he 
column oven was kept at 40°C throughout the 
analysis. The eluent was ionized by positive 
electrospray ionization mode and detected by mass 
spectrometry. 
 
Mass Spectrometric condition 
Mass spectrometric data were acquired in positive ion 
mode with the following ESI-MS parameters: curtain 
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gas low rate 15 psi; collision gas low rate 10 psi; ion 
source gas (Gs1 and Gs2) were 40 psi and 45 psi, 
respectively; ion spray voltage 5500 V; dwell time 
for each transition 200 ms; inter channel delay was 5 
ms and transfer capillary temperature is 550°C. he 
curtain gas and ion source gases were nitrogen. Data 
were recorded in MRM mode. MS/MS optimization 
for metaxalone and phenytoin were performed using 
100ng/mL concentrations. he precursor ions and LC-
MS/MS parameters are displayed in Table 1. 
 
Preparation of stock and standard solutions 
The metaxalone standard was weighed twice 
separately and prepared separately using methanol 
and water (1:1) to yield two primary standard stock 
solutions (1 and 2) with a concentration of 1 mg/mL. 
Secondary and working stock solutions for the 
calibration curve were prepared from metaxalone 
primary stock solution-1 by methanol and water 
(1:1). The quality controls working stock solution 
were prepared from primary stock solution-2 by 
methanol and water (1:1). hese working stock 
solutions (1 and 2) were further diluted to obtain 
metaxalone calibration spiking stock solution for the 
inal concentrations of 0.98, 1.95, 3.90, 7.80, 15.61, 
31.18, 62.37, 124.75, 249.50, 499.00, 998.00 ng/mL 
and concentrations of (2.94, 399.2, and 798.4 ng/mL) 
quality control spiking stock solutions were prepared. 
he internal standard (Phenytoin) was weighed and 
prepared separately using methanol and water (1:1) to 
obtain a primary stock solution of 1 mg/mL. he 
working internal standard solution with a 
concentration of 200 ng/mL was prepared by diluting 
the primary stock solution with methanol. 
 
Extraction of metaxalone from rat plasma 
Extraction of metaxalone from rat plasma sample was 
carried out by using simple protein precipitation 
method. he protein precipitation was carried using 
methanol with 0.1% trichloroacetic acid as 
precipitating agent. he calibration curve sample 
preparation involves using 47.5 μl of rat plasma and 
2.5 μl of calibration curve spiking solutions. From 
this mixture take 25 μl add 350 μl of methanol 
containing 0.1% trichloroacetic acid and 25 µl of 
internal standard in methanol. For the samples 25 µl 
of vortexed plasma was taken and 350 µl of methanol 
containing 0.1% trichloroacetic acid and 25 µl of 
internal standard in methanol was added. 
The Calibration curve samples and sample mixtures 
were vortexed for 5 min at 885 g and centrifuged at 
19283 g for 10 min. hen 300 μl of supernatant was 
collected and transferred into the glass vials 
containing plastic inserts and subjected to LC-
MS/MS analysis. he representative chromatograms 
were shown in Figure 2. 
 
Bioanalytical method validation 
Preparation of calibration curve: he linearity of the 
method was evaluated by a calibration curve in the 
range of 0.98 – 998ng/ mL of metaxalone, including 
lower limit of Quantitation (LLOQ). he calibration 
curve was achieved by plotting the peak area ratios of 
metaxalone and internal standard versus the 
concentration of metaxalone by least-squares linear 
regression analysis. he calibration curve requires a 
correlation coeicient (R2) of >0.99. he acceptance 
criteria for each back-calculated standard 
concentration should be within 15% of the nominal 
concentration, except it should not exceed 20% for 
the LLOQ. Each validation run consisted of a double 
blank, system suitability sample, a zero standard, 
calibration curve consisting of ten non-zero samples 
covering the total range (0.98 – 998 ng/mL) and QC 
samples at three concentrations (N = 6, at each 
concentration). Such validation runs were generated 
on six consecutive days. 
 
Table 1: Mass Spectrometric condition. 
 
Mass Spectrometric Condition 
Name of compound Analyte: Metaxalone Internal standard Phenytoin 
Molecular weight of free compound 
(base / acid) 
221.252 252.268 
MRM transitions (m/z) 222.2/161 253.2/182.2 
Declustering potential (eV) 61 75 
Entrance potential (eV) 10 10 
Collision energy (eV) 20 25 
Collision cell exit potential (eV) 13 13 
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Accuracy and precision:  
Intra-day and Inter-day accuracy and precision were 
determined by duplicate analysis of six sets of 
samples spiked with four diferent concentrations of 
metaxalone at low, medium, high quality control 
samples (0.98, 399.1,798.4 ng/mL) including LLOQ 
(0.98 ng/mL) within a day or on 6 consecutive days. 
For acceptance criteria for intra and inter-day 
precision, accuracy should be within 85–115% of the 
nominal concentration and coeicient of variation 
(%CV) values should be <15% over the calibration 
range, except at the LLOQ, where accuracy should be 
between 80 – 120% and %CV should not be more 
than 20% 
Selectivity:  
The selectivity of the assay methodology was 
established using a minimum of six independent 
sources of the same matrix. here were no 
interferences from the endogenous material at the 
retention time for both metaxalone and internal 
standard (Phenytoin). Therepresentative 
chromatogram is shown in Figure 3. 
Recovery:  
Recovery of metaxalone was evaluated by comparing 
the mean peak areas of three extracted low, medium 
and high quality control samples to mean peak areas 
of three neat reference solutions (un-extracted). 
Recovery of internal standard was evaluated at a 
concentration of 200 ng/mL and corresponding mean 
peak area of the extracted samples compared to the 
mean peak areas of neat reference solutions. 
Recovery of the analyte need not be 100%, but the 
extent of recovery for analyte (metaxalone) and 
internal standard (Phenytoin) should be consistent 
and reproducible. 
Stability:  
In order to ind out the stability of metaxalone in rat 
plasma, bench top stability, freeze thaw stability, auto 
injector stability and long term stability studies were 
carried out by using six replicates of the low and high 
plasma quality control samples. For the bench top 
stability, frozen plasma samples were kept at room 
temperature for 24 hr before sample preparation. 
Freeze–thaw stability of the samples was obtained 
over three freeze-thaw cycles, by thawing at room 
temperature for 2–3 hr and refrozen for 12–24 hr for 
each cycle. Auto sampler stability of metaxalone was 
tested by processed and reconstituted low and high 
plasma QC samples, which were injected 24 hr ater 
reconstitution and were compared with freshly 
prepared QC samples. Long term stability of 
metaxalone in rat plasma was tested ater storage at 
approximately −70°C for 30 days. For the acceptance 
criteria of stability, the deviation compared to the 
freshly prepared standard should be within ± 15% of 
the nominal concentration. 
Matrix efect:  
The matrix efect was performed in 6 diferent lots of 
rat plasma by taking 47.5 µl of rat plasma and 2.5 µl 
of methanol: water (1:1) solution. From the mixture, 
take 25 µl and add 375 µl of blank methanol 
containing 0.1% trichloroacetic acid. his blank 
mixture was vortexed for 5 min at 885 g and 
centrifuged at 19283 g for 8 min to prepare the 
extracted blank. he aqueous equivalent solution was 
prepared by taking 25 µl of water and adding 25 µl of 
internal standard along with 350 µl of methanol 
containing 0.1% trichloroacetic acid. he extracted 
blank supernatant and aqueous equivalent solution 
were mixed in a ratio of (1:1) solution. he blank 
aqueous solution was prepared by mixing 25 µl of 
water along with 375 µl of methanol and subjected to 
vortexing. The neat solution and post extracted 
solution. Were prepared by mixing aqueous 
equivalent solution to both extracted blank and blank 
aqueous solution in a ratio of (1:1) solution. Both 
solutions were vortexed and subjected to LC-MS/MS 
for analysis. 
Matrix suppression or enhancement was calculated as 
follows: 100×mean peak area of post extracted 
sample/mean peak area of neat standard solution. The 
acceptance criteria for matrix efect implied that the 
%CV should be less than 15% of matrices tested and 
at least 80% of matrices should meet the above 
criteria. he results obtained were displayed in Table 
2. 
 
Table 2: Calibration table 
Day R Slope Intercept 
1 0.9998 0.0001545 -0.06045 
2 0.9997 0.0001526 -0.06333 
3 0.9996 0.0001535 -0.06681 
4 0.9998 0.0001549 -0.06632 
5 0.9997 0.0001562 -0.0619 
6 0.9996 0.0001552 -0.06101 
Mean 
0.9997 0.0001544 -0.06330 
SD 8.944E-05 1.277E-06 0.0027 
SE 3.652E-05 5.213E-07 0.0011 
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Table 3: Intraday precision and accuracy (n=6). 
Concentration 
added (ng/ml) 
Concentration found 
(mean ± SD) (ng/ml ) 
%CV %Bias 
0.98 0.96 ± 0.019 1.72 -1.49 
2.94 2.91 ± 0.033 1.45 -1.25 
400 398.11 ± 1.390 1.40 -2.45 
800 787.26 ± 1.993 1.89 -3.67 
 
Table 4: Interday Accuracy and precision (n=6). 
Concentration added 
(ng/ml) 
Concentration found 
(mean ± SD) (ng/ml ) 
%CV %Bias 
 
0.98 0.97 ± 0.034 1.98 -1.40 
2.94 2.85 ± 0.133 1.99 -2.31 
400 390 ± 0.520 1.41 -1.90 
800 802.24 ± 1.675 1.67 -3.05 
 
Table 5: Extraction Recovery (n=6). 
Metaxalone LQC % MQC% HQC% 
Extraction recovery of 
six different aliquots of 
rat plasma 
81.22 83.15 82.11 
83.05 82.21 83.97 
82.23 84.11 82.14 
84.13 83.17 84.12 
82.02 82.21 83.13 
81.55 83.16 84.21 
Mean of extraction 
recovery 82.36 83.00 83.28 
Phenytoin (IS) 
82.88 ± 1.28 
82.05 ± 1.25 
 
Table 6: Matrix effect (n=6). 
 
 
Metaxalone 
LQC(ng/ml) HQC(ng/ml) 
Aqueous Post Extracted Aqueous Post Extracted 
 
 
 
 
Peak areas 
6469 5679 1842799 1711811 
6404 5693 1821364 1716685 
6264 5675 1839656 1722664 
6108 5584 1813150 1725528 
6328 5866 1842968 1721779 
6311 5722 1838605 1705920 
Mean peak area  6314.6 5699.4 1831987 1719693.4 
Relative 
standard 
deviation 1.968627 1.618601 0.690661 0.43241655 
Absolute matrix 
effect 90.257 93.870 
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Table 7: Stability details of Metaxalone in rat plasma sample (n=6). 
 
 
Concentration 
(ng/ml) 
 
Fresh sample  
Concentration 
(ng/ml)         
 
Sample 
Concentration after 
storage(ng/ml)   
 
%CV      
 
%Bias 
Short term (24hr) 
2.94 2.97 2.88 1.73 -2.30 
800 795.11 780.24 1.37 -2.75 
Three Freeze thaw cycles 
2.94 2.94 2.80 1.34 -0.98 
800 804.86 781.20 2.31 -2.25 
Auto sampler stability (24 hr) 
2.94 2.99 2.91 1.76 -1.46 
800.00 814.23 785.65 1.54 2.35 
Long term 30 days (-85°C) 
2.94 2.93 2.76 2.79 -2.33 
800.00 797.25 760.21 1.31 -3.70 
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RESULTS 
Selectivity and optimization of chromatographic 
conditions 
Plasma matrices were obtained from six diferent 
sources and assayed to evaluate the selectivity of the 
method and the detection of interference. Metaxalone 
and Phenytoin (internal standard) were well separated 
from the co-extracted material under the described 
chromatographic conditions at retention times of 1.60 
and 1.83 min respectively. No endogenous peak from 
plasma was found to interfere with the elution of 
either the drug or the internal standard. The LLOQ 
which could be measured with acceptable accuracy 
and precision for the analyte 0.98 ng/mL was 
established (Figure 4). It indicates that the proposed 
method is highly selective and speciic. Moreover this 
method does not require any gradient mobile phase 
system with high sample clean up and less time 
consumption and can also be automated 
Calibration curve 
Linear detector response for the peak-area ratios of 
the metaxalone to internal standard was observed in 
the concentration range between 0.98 - 998 ng/mL 
with a mean correlation coeicient of 0.9998. he 
reason for choosing a wide calibration range for 
metaxalone PK study is to analyze samples of higher 
and lower dose concentration and diferent route of 
administration like intravenous administration and 
per oral where the Cmax concentration will be higher 
for intravenous. he best it for the calibration curve 
could be achieved with the linear equation Y = MX + 
C. he mean linear regression equation of calibration 
curve for the analyte was Y = 0.0001545x-0.06045, 
where Y was the peak area ratio of the analyte to the 
IS and X was the concentration of the analyte. he 
results were given in the Table 3. 
 
Accuracy and precision 
The intra-day accuracy and precision ranged between 
95.3-105.11%, and 1.40-1.89%, respectively. he 
inter-day accuracy and precision ranged from 94.85 
to 109.26% and 1.41 to 1.98%, respectively. The 
accuracy and precision for intra and interday at the 
LLOQ and at LQC, MQC, HQC control samples of 
metaxalone in plasma were within acceptable limits 
(N = 6). The results of the method validation studies 
presented in Table 4 and 5. 
 
Recovery 
The recovery of metaxalone in plasma was calculated 
at three QC levels. he response (extracted) compared 
to that of unextracted samples of the reference 
solution. The percentage recovery of metaxalone and 
phenytoin (internal standard) were found to be above 
80%. Results are displayed in the Table 6.  
 
 
 
Stability  
Stock solutions of metaxalone (1 mg/mL) and 
internal standard (1 mg/mL) were separately 
prepared. he solutions were stable for at least 1 
month when stored under light-protected conditions 
at 4°C. he stability experiments were aimed at testing 
all possible conditions that the samples might 
experience ater collecting and prior the analysis. All 
stability results were summarized in Table 7. he 
results of three freeze– thaw cycles and bench top 
stability testing (24 h) when the spiked samples were 
kept at room temperature indicated that metaxalone 
was stable in rat plasma under these conditions. 
Analyte spiked QC samples were stable for at least 
30 days if stored in the freezer at −85°C. Testing of 
auto sampler stability of quality control samples 
indicated that metaxalone would be stable when kept 
in the auto sampler up to 24 h. 
 
Application of the method 
The assay is sensitive enough to measure the plasma 
concentration time proile ater oral administration of 
10 mg/kg dose of metaxalone in a group of 3 male 
SD rats weighing about 200-250 g under fasted 
condition. he blood is collected by jugular vein 
cannulation at the following time intervals 0.08, 0.25, 
0.5, 1, 2, 4, 6, 8, 12, 24 hrs and the collected blood 
was centrifuged at 6287 g for 5 min to aliquot out the 
plasma. he resultant plasma had been successfully 
employed for the quantitative estimation of 
metaxalone in samples. he concentration time proile 
curve for metaxalone is shown in Figure 5. 
 
DISCUSSION: 
LCMS/MS optimization 
The LC-MS/MS method for the detection of 
metaxalone in rat plasma was investigated. 
Metaxalone was dissolved in methanol: water (1:1) to 
obtain the primary stock solution followed by 
subsequent dilution in methanol (for tuning) and was 
directly introduced into the mass spectrometer. By 
optimizing ESI source (ionization) and mass 
parameters such as collision energy, entrance 
potential, declustering potential, collision cell exit 
potential and CAD gas (N2) the protonated molecular 
ions of metaxalone were obtained. he most suitable 
collision energy was determined by observing the 
maximum response obtained for the fragment ion 
peak m/z. he product ion mass spectra of the analyte 
and internal standard are presented in Table 1 where 
the [M+H]+ ion of the analyte and internal standard 
were selected as precursor ions. he most abundant 
fragment ions at m/z 222.2/161.0, and 253.2/182.2 
were chosen in the MRM acquisition for metaxalone 
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and the internal standard, respectively. 
During the early stages of method development, 
attempts were made to optimize ESI as an ionization 
method for metaxalone analysis. In the ESI full scan 
Q1 spectra of metaxalone, the most intensive [M+H]+ 
ion was observed along with the less abundant 
[M+H+CH3OH]+ ion and other ions. When the 
source (CAD) energy and collision energy (CE) was 
set, the abundance of [M+H]+ ion increased whereas 
other mass ions like [2M+H]+ and [M+H+CH3OH]+ 
decreased. When standard working stock solutions of 
the analyte were directly injected into the mass 
spectrometer system, it was observed that the 
response for the analyte was linear over the 
mentioned calibrated range. he linearity was found to 
be best it for the calibration range when the 
compound was dissolved in methanol: water (1:1) for 
preparing the working stock solution. he bufer pH at 
3.0 helped in increasing the linear response by 
inluencing the column properties like retention time, 
peak shape and peak response with relative variation 
of 15% for the analyte. It is accepted as a fact that a 
non linear range would not be adequate to the 
pharmacokinetic study. But by controlling the 
variable parameters like solubility, pH, column, 
temperature, ionization, less injection volume, 
obtaining a huge linear range with less possible 
relative error is possible. As per this method, low rate 
and injection volume was set at 0.6 mL/min and 5 µL 
injection volume. Unlike reported paper [10], split 
was not employed in this method because of low low 
rate. Since the basic concept of increasing the low 
rate with high split ratio of 10:90 is to fasten the 
elution time and simultaneously maintain ionization 
for high low rates through mass. Generally split ratio 
tends to change with changes in back pressure and 
expensive in terms of high solvent consumption. But, 
in this method, no split employed and that possibly 
decreases solvent consumption, improves 
reproducibility, increase column life and 
simultaneously declines chemical noise. It is also 
important to compare the column length, since this 
method involves shorter column length (100 mm x 
4.6 mm), indicating fast elution with shorter run time. 
he Cmax found for rat (intra peritoneal dose) was 
below 900 ng/mL, but the reason for huge linearity 
range is to make sure that the method is capable for 
analyzing higher and lower concentration obtained 
from both Intravenous and per oral dose of 
metaxalone. Hence, this method is validated for the 
linearity range from 0.98 – 998 ng/mL. During an 
early phase of method development attempts were 
made to choose the right column, since the columns 
like Kromasil C8, Phenomenex Luna C8, Waters 
symmetry C8, showed that the analyte eluted within 
the void volume with bad peak shape and poor area 
response, but as we tried to improve retention time 
through C18 columns, even though the area response 
and peak shape was improved considerably. he best 
C18 column, chosen based on separation, 
reproducibility, and response. Taking into account 
the non polarity nature of the metaxalone, liquid 
liquid extraction had been proven to be an efective 
technique in the published methods. However, liquid 
liquid extraction was found to be time consuming, 
cost expensive, requires personal manipulation. 
When a huge number of samples have to be analyzed, 
it is a potential source of errors. Also, most of these 
methods lacks sensitivity and needs relatively large 
volumes of sample (≥0.200 mL) and solvents for 
analysis. Consequently, these methods are found to 
be unsatisfactory for pharmacokinetic application 
studies involving small laboratory animals like 
rodents. herefore, diferent trails are taken with 
protein precipitation method for the sample 
preparation to make processing simpler and less time 
consuming for analysis. Diferent extraction trials was 
carried out at acidic, neutral and alkaline pH in 
diferent protein precipitating solvents, showed that 
the metaxalone could be quantitatively extracted 
from plasma when acidiied with 0.1% trichloroacetic 
acid in methanol. Employing a combination of 
methanol and trichloroacetic acid resulted in high 
recovery of analyte without increase in endogenous 
peaks. he trichloroacetic acid acts by ion pairing 
mechanism which acts by ion pairing to the molecule 
and decreases/increases its hydrophilicity/ 
hydrophobicity and resulting in enhanced recovery of 
the analyte. 
Since ESI positive ion mode shows good sensitivity, 
selectivity and speciicity, the ESI source was chosen 
for this wider linear range for the analyte. In addition 
during sample preparation, by liquid liquid 
extraction, it is required to reconstitute the residues 
with the mobile phase but in protein precipitation 
method, the analyte is injected into the LC-MS/MS 
with the same extracted organic solvent. 
Since, the reported bioanalytical methods for the 
estimation of metaxalone by HPLC-UV, and mass 
spectrometry demonstrated that the methods were 
more tedious and time consuming. But, the present 
method is simple and robust for fast high throughput 
samples analysis with less analysis cost for analyzing 
metaxalone in biological samples. he reported 
bioanalytical methods were mainly designed using a 
relatively large volume of plasma sample (200 µl). 
However, in case of preclinical pharmacokinetic and 
toxic kinetic studies on rodents like rats and mice, in 
which only microlitre quantities of plasma samples 
are available for single time bioanalysis, but in case 
of reanalysis or incurred sample reanalysis, these 
method reported might not be suitable. hese reported 
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methods depend on high sample volume because of 
its low sensitivity and it is inadequate to calculate the 
lesser concentration with good speciicity due to 
background chemical noise and interference from 
biological matrix. 
In this proposed method, no interfering peaks were 
observed at the elution times of metaxalone and 
phenytoin (IS). he method also had suicient 
selectivity, speciicity, precision and accuracy over 
the concentration range of 0.98–998 ng/mL. this 
method had a quantiication limit of 0.98 ng/mL, 
which was adequate enough to quantify the drug in 
rat plasma ater administration of metaxalone. he 
developed method requires very low sample volume 
(25 µL). Hence a minimum blood sampling is 
suicient; thereby making pharmacokinetic blood 
sampling study of a single rodent is practicable. 
 
CONCLUSION: 
Since merits of LC compare to other techniques are 
well recognized, a highly sensitive, speciic and 
reproducible isocratic LC method with mass 
detection method is more valuable. In addition, along 
with method development, the method is also 
validated to quantify the concentration range of 0.98 
– 998 ng/mL of metaxalone in rat plasma samples 
and requires only 25 µL of sample volume. he LC-
MS/MS method presented here fulils the criteria 
generally required for the bioanalytical assays. This 
assay has suicient sensitivity, selectivity and recovery 
above 80%, which shows that the method is suitable 
for pharmacokinetic and toxic kinetic studies of 
metaxalone. The small sample volume requirement 
supports the possibility to study the full PK proile in 
individual small rodents like mice, rats. 
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